| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Butterfly Network | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $370.76M | Series D | 9/27/2018 | $250M | $1.28B | $10.27 | Bill & Melinda Gates Foundation, Fidelity Investments, Fosun Pharma, Jamaie Dinan | ||||
 | Prime Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $315.76M | Series B | 7/13/2021 | $200M | $1.23B | $4.38 | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price | ||||
 | Auris Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $738.23M | Series D-1 | 11/28/2018 | $220.42M | $2.13B | $0.21 | Partner Fund Management, Wellington Management, D1 Capital Partners, Senator Investment Group, Mithril Capital Management, Lux Capital, Viking Global Investors | ||||
 | Elemy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $274.4M | Series B | 10/6/2021 | $211.59M | $1.14B | $29.73 | SoftBank, Goodwater Capital, Premji Invest, Metrodora Ventures, Amity Ventures, Avidity Partners, Whale Rock Capital Management, Sound Ventures | ||||
 | Olive | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $837.59M | Series H | 7/1/2021 | $450.32M | $4B | $14.13 | Vista Equity Partners, Base10 Partners Advancement Initiative | ||||
 | Parallel | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $228.07M | Series D | 6/27/2019 | $130.89M | $2.47B | $43.63 | Ed Brown | ||||
 | Thirty Madison | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $649.53M | Series 2-M | 3/14/2022 | $72.53M | $1.11B | $11.63 | Undisclosed Investors | ||||
 | TrueBinding | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.08M | Series D-1 | 3/17/2023 | $46.08M | $1.21B | $5.08 | Wangsu | ||||
 | Essence Healthcare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $473.31M | Series 5-A2 | 4/2/2024 | $50M | $1.36B | $2.31 | Undisclosed Investors | ||||
 | Immunai | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.22M | Series C-1 | 10/27/2021 | $204.34M | $1.15B | $186.65 | Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON | ||||
 | Somatus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.41B | Series Junior-2NV | 6/27/2025 | $300M | $4.98B | $1.32K | Undisclosed Investors | ||||
 | Treeline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.1B | Series A-2 | 9/3/2025 | $200.1M | $1.83B | $8.61 | Access Industries, ARCH Venture Partners, OrbiMed, GV, KKR, T. Rowe Price Associates, Ajax Health, Casdin Capital, Fidelity, Aisling Capital, Rock Springs Capital, Exor | ||||
 | Adaptive Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $561.37M | Series F-1 | 1/4/2018 | $45M | $1.35B | $10.67 | Microsoft | ||||
 | Areteia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $360M | Series A-1 | 2/21/2025 | $180M | $1.13B | $10.00 | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | ||||
 | Bellabeat | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.26M | Series C | 9/22/2022 | $21.57M | $1.01B | $35.95 | Frontierspace Ventures | ||||
 | Inscripta | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $459.69M | Series E | 4/5/2021 | $150M | $1.32B | $8.83 | Fidelity, T. Rowe Price | ||||
 | Intarcia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $961.46M | Series EE | 9/15/2016 | $475.68M | $3.94B | $60.00 | Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group | ||||
 | Nutcracker Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $244.06M | Series C | 3/14/2022 | $167.76M | $1.09B | $10.75 | ARCH Venture Partners | ||||
 | Pomelo Care | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $171.07M | Series C | 1/8/2026 | $92M | $1.7B | $151.14 | Stripes, Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, SV Angel | ||||
 | Reify Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $490.2M | Series D | 4/21/2022 | $230.78M | $4.78B | $11.11 | Altimeter Capital, Coatue Management, Dragoneer Investment Group, ICONIQ Growth, Adams Street, Battery Ventures | ||||
 | American Well | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $674M | Series C | 5/20/2020 | $617M | $1.03B | $45.00 | InVenture Partners, Anthem, Teva Pharmaceutical Industries, Allianz X, Philips, Martin Ventures, Hanaco Venture Capital, Cito Ventures, ADIP, Echo Health Ventures, McKesson Ventures, Waterline Ventures, Westway Capital, SV Health Investors | ||||
 | Sema4 | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $368.26M | Series C | 7/29/2020 | $121.4M | $1.47B | $613.67 | BlackRock, Deerfield Management Company, Moore Strategic Ventures, Blackstone, Section 32, Oak HC/FT, Decheng, Connecticut Innovations | ||||
 | Clover Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $676.33M | Series D | 5/10/2017 | $130M | $1.23B | $9.38 | Baillie Gifford, Expanding Capital, First Round Capital, Greenoaks Capital, GV, Palm Drive Capital, Sequoia Capital, Toba Capital, Western Technology Investment | ||||
 | EQRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $813.88M | Series B | 1/11/2021 | $570M | $1.66B | $2.74 | GV, Bain Capital Life Sciences, Andreessen Horowitz, ARCH Venture Partners, Arboretum Ventures, Casdin Capital, Nextech, Section 32 | ||||